🟢 Recursion Pharmaceuticals is trading 5.48% up today amid trial updates and Sanofi's $10 million milestone

Recursion Pharmaceuticals is trading at $3.94, up 5.48%, amid October 15 clinical updates and a Sanofi milestone announcement.

• Recursion reported encouraging updates for REC-4881 and REC-1245, including a 47% median polyp-burden reduction and responses in the REC-1245 trial.
• Sanofi optioned a development candidate, triggering a $10 million milestone payment. The same-day news is a plausible company-specific catalyst, though coverage does not explicitly attribute the live gain to it.
• Recursion also priced a $200 million stock offering, a competing dilution-related consideration.